The FDA is clear on this, you can either:
1. Get excellent clinical efficacy results with no safety issues and they don't really care about replicating the mechanism of action in-vivo with in-vitro, or;
2.
Source: https://pink.citeline.com/-/media/supporting-documents/pink-sheet/2020/08/fda-briefing-document-on-remestemcel-l-am-session.pdf?rev=222f51497a0f49c294091e6ad844115c&hash=93D88D09ED488698D719E3EA21DD7334
The Phase I/IIb Nereid Study Is Now Registered, page-20
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.010(3.70%) |
Mkt cap ! $50.29M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 28.0¢ | 26.5¢ | $22.71K | 82.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3076 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 15941 | 2 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.0¢ |
Change
0.010 ( 5.88 %) |
||||
| Open | High | Low | Volume | ||
| 27.0¢ | 27.5¢ | 26.0¢ | 67345 | ||
| Last updated 13.55pm 16/05/2024 ? | |||||
| CYP (ASX) Chart |